We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Miss
Camelia
Vladescu
Camelia.vladescu@nhs.net
Dr
Nichola
Cooper
n.cooper@imperial.ac.uk
Elena
Ferrer
e.ferrer@imperial.ac.uk
Coagulation defects, purpura and other haemorrhagic conditions
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Infections, including Helicobacter pylori (H. pylori), have been implicated in the pathogenesis of immune thrombocytopenia (ITP). H. pylori affects the gut microbiome.
Dysregulation of immune function mediated by the disturbance of the gut microbiome and the host-microbe interactions has already been shown to play an important role in the pathophysiology of other autoimmune diseases. There is anecdotal evidence that the use of antibiotics, probiotics, and intermittent fasting leads to a significant increase in the platelet count in some ITP patients.
We believe the gut microbiome may also play a role in the pathophysiology of ITP. By analysing the gut microbiome of the ITP population, we may identify clues for better treatments and biomarkers to stratify patients and optimise treatment.
Hypothesis: the gut microbiome of patients with ITP is altered compared to that of healthy controls.
If we identify changes in the gut microbiome of ITP patients, our data may be used to design a prospective trial to alter the gut microbiome in ITP patients (either through diet, the use of antibiotics or faecal microbiota transplants), more directed treatment for this condition than current therapies.
The UK incidence of adult ITP is estimated to be around 120 per year and 3000–4000 people are affected at any one time. At the haematology clinic in the Hammersmith Hospital we visit 100 patients with ITP per month.
We aim to recruit 60 participants, 20 patients with recurrent ITP, 20 with refractory ITP and 20 healthy controls, if possible, accompanying relatives to ITP patients to reflect similar behavioural and nutritional habits. Participants will be offered to participate in the haematology clinic and once informed consent is provided, a blood, urine and stool samples will be collected and 4 questionnaires completed. No follow up is required.
The study is funded by the Imperial Health Charity.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
1. Antibiotic use in the month prior to enrolment in the study 2. Pregnant or breast-feeding 3. History of moderate to severe gastrointestinal and cardiovascular diseases, diabetes or metabolic syndrome 4. History of bowel surgery, documented inflammatory bowel disease or irritable bowel syndrome 5. History of other autoimmune diseases 6. Current diagnosis and/or treatment of malignancies 7. Age < 18 or > 65 years 8. Steroids use within 3 days before study enrolment.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Elena
Ferrer
e.ferrer@imperial.ac.uk
Dr
Nichola
Cooper
n.cooper@imperial.ac.uk
Miss
Camelia
Vladescu
Camelia.vladescu@nhs.net
The study is sponsored by IMPERIAL COLLEGE HEALTHCARE NHS TRUST and funded by ITP SUPPORT ASSOCIATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 57066
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
